All articles tagged with #insilico medicine
Insilico Medicine used generative artificial intelligence to design rentosertib, a small-molecule drug for a chronic lung condition. New clinical-trial data reported in Nature Biotechnology indicate the AI-designed drug reduced biological aging markers across six aging clocks, suggesting a potential to slow aging—but further research is needed to confirm safety, efficacy, and applicability beyond the lung disease context.
Eli Lilly and Insilico Medicine have agreed to a commercialization deal valued at up to $2.75 billion (including $115 million upfront) to develop, manufacture, and bring to market Insilico’s AI-discovered preclinical oral drug candidates, with milestones tied to regulatory and commercial success. The companies deny rumors of a full acquisition, and specific asset details aren’t disclosed, though a GLP-1 candidate has been licensed to an undisclosed partner.
Eli Lilly agreed to a $2.75 billion deal to bring AI‑discovered drugs from Insilico Medicine to the global market, with $115 million upfront and remaining milestones plus royalties. Insilico has developed about 28 AI‑driven drug candidates, roughly half in clinical stages, and will join Lilly’s Gateway Labs; the collaboration—dating to a 2023 AI software license—aims to accelerate discovery across multiple disease areas as Lilly expands its AI‑driven R&D and China investment strategy.
U.S. drugmaker Eli Lilly is poised to sign a roughly $2 billion deal with Hong Kong-listed Insilico Medicine to use AI in drug discovery, securing exclusive rights to sell Insilico’s GLP-1 diabetes drug with an upfront $115 million and potential milestone payments that could lift the total beyond $2 billion, underscoring Lilly’s China-focused expansion and its heavy AI investment in pharma.
Insilico Medicine, an AI-driven biotech company, has developed an AI-designed drug, ISM5411, for inflammatory bowel disease (IBD) that has entered Phase I clinical trials. The drug targets a protein that regulates gut barrier protection genes and aims to treat IBD in a new way. Current IBD drugs have limitations, and ISM5411 is designed to promote mucosal repair and restore normal gut functioning. The drug is being tested for safety and tolerability in healthy volunteers, with plans for international multi-center trials. While promising, AI-generated drugs like ISM5411 may carry inherent risks and require public awareness and education as they move from research labs to clinical settings.
Insilico Medicine, an AI-driven biotech company, has announced that its AI-designed drug for COVID-19 has entered Phase I clinical trials. The oral drug, if approved, would become the first-ever alternative to Paxlovid and has shown effectiveness against all variants of the virus. It is also more stable and works for a longer period of time compared to Paxlovid. The new drug is easy to produce in large quantities and is currently being evaluated for safety and tolerability in healthy volunteers. The results of the clinical trials are expected to be released by the end of 2023.